The metabolomics quality assurance and quality control consortium (mQACC) evolved from the recognized need for a community-wide consensus on improving and systematizing quality assurance (QA) and quality control (QC) practices for untargeted metabolomics.
In this work, we sought to identify and share the common and divergent QA and QC practices amongst mQACC members and collaborators who use liquid chromatography-mass spectrometry (LC–MS) in untargeted metabolomics.
All authors voluntarily participated in this collaborative research project by providing the details of and insights into the QA and QC practices used in their laboratories. This sharing was enabled via a six-page questionnaire composed of over 120 questions and comment fields which was developed as part of this work and has proved the basis for ongoing mQACC outreach.
For QA, many laboratories reported documenting maintenance, calibration and tuning (82%); having established data storage and archival processes (71%); depositing data in public repositories (55%); having standard operating procedures (SOPs) in place for all laboratory processes (68%) and training staff on laboratory processes (55%). For QC, universal practices included using system suitability procedures (100%) and using a robust system of identification (Metabolomics Standards Initiative level 1 identification standards) for at least some of the detected compounds. Most laboratories used QC samples (>86%); used internal standards (91%); used a designated analytical acquisition template with randomized experimental samples (91%); and manually reviewed peak integration following data acquisition (86%). A minority of laboratories included technical replicates of experimental samples in their workflows (36%).
Although the 23 contributors were researchers with diverse and international backgrounds from academia, industry and government, they are not necessarily representative of the worldwide pool of practitioners due to the recruitment method for participants and its voluntary nature. However, both questionnaire and the findings presented here have already informed and led other data gathering efforts by mQACC at conferences and other outreach activities and will continue to evolve in order to guide discussions for recommendations of best practices within the community and to establish internationally agreed upon reporting standards. We very much welcome further feedback from readers of this article.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
The questionnaire data reported in this paper has been organized and blinded into an excel spreadsheet and are available in Supplementary Material 2.
Beger, R. D., Dunn, W. B., Bandukwala, A., Bethan, B., Broadhurst, D., Clish, C. B., et al. (2019). Towards quality assurance and quality control in untargeted metabolomics studies. Metabolomics, 15, 4.
Bijlsma, S., Bobeldijk, I., Verheij, E. R., Ramaker, R., Kochhar, S., Macdonald, I. A., et al. (2006). Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Analytical Chemistry, 78, 567–574.
Blacher, E., Bashiardes, S., Shapiro, H., Rothschild, D., Mor, U., Dori-Bachash, M., et al. (2019). Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature, 572, 474–480.
Bouhifd, M., Beger, R., Flynn, T., Guo, L., Harris, G., Hogberg, H., et al. (2015). Quality assurance of metabolomics. Altex, 32, 319–326.
Bouhifd, M., Hartung, T., Hogberg, H. T., Kleensang, A., & Zhao, L. (2013). Review: toxicometabolomics. Journal of Applied Toxicology, 33, 1365–1383.
Broadhurst, D., Goodacre, R., Reinke, S. N., Kuligowski, J., Wilson, I. D., Lewis, M. R., et al. (2018). Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics, 14, 72.
Burrage, L. C., Thistlethwaite, L., Stroup, B. M., Sun, Q., Miller, M. J., Nagamani, S. C. S., Craigen, W., Scaglia, F., Sutton, V. R., Graham, B., Kennedy, A. D., Members of the, U., Milosavljevic, A., Lee, B. H. & Elsea, S. H. (2019). Untargeted metabolomic profiling reveals multiple pathway perturbations and new clinical biomarkers in urea cycle disorders. Genet Med, 21, 1977–1986.
Cao, Z., Miller, M. S., Lubet, R. A., Grubbs, C. J., & Beger, R. D. (2019). Pharmacometabolomic pathway response of effective anticancer agents on different diets in rats with induced mammary tumors. Metabolites, 9(7), 149.
Chen, L., He, F. J., Dong, Y., Huang, Y., Harshfield, G. A., & Zhu, H. (2019). Sodium reduction, metabolomic profiling, and cardiovascular disease risk in untreated black hypertensives. Hypertension, 74, 194–200.
Cirulli, E. T., Guo, L., Leon Swisher, C., Shah, N., Huang, L., Napier, L. A., et al. (2019). Profound perturbation of the metabolome in obesity is associated with health risk. Cell Metabolism, 29(488–500), e2.
Crestani, E., Harb, H., Charbonnier, L. M., Leirer, J., Motsinger-Reif, A., Rachid, R., et al. (2019). Untargeted metabolomic profiling identifies disease-specific signatures in food allergy and asthma. The Journal of Allergy and Clinical Immunology, 145(3), 897–906.
Dudzik, D., Barbas-Bernardos, C., Garcia, A., & Barbas, C. (2018). Quality assurance procedures for mass spectrometry untargeted metabolomics. a review. Journal of Pharmaceutical and Biomedical Analysis, 147, 149–173.
Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., Anderson, N., et al. (2011). Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols, 6, 1060–1083.
Dunn, W. B., Broadhurst, D., Edison, A., Guillou, C., Viant, M. R., Bearden, D. W., et al. (2017). Quality assurance and quality control processes: summary of a metabolomics community questionnaire. Metabolomics. https://doi.org/10.1007/s11306-017-1188-9.
Dunn, W. B., Lin, W., Broadhurst, D., Begley, P., Brown, M., Zelena, E., et al. (2015). Molecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics, 11, 9–26.
Dunn, W. B., Wilson, I. D., Nicholls, A. W., & Broadhurst, D. (2012). The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans. Bioanalysis, 4, 2249–2264.
Eurachem/CITAC Guide (2016). Guide to quality in analytical chemistry: An aid to accreditation. In: BARWICK, V. (ed.) 3rd ed.
Gafson, A. R., Savva, C., Thorne, T., David, M., Gomez-Romero, M., Lewis, M. R., et al. (2019). Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm, 6, e562.
Gangler, S., Waldenberger, M., Artati, A., Adamski, J., van Bolhuis, J. N., Sorgjerd, E. P., et al. (2019). Exposure to disinfection byproducts and risk of type 2 diabetes: A nested case-control study in the HUNT and Lifelines cohorts. Metabolomics, 15, 60.
Gika, H. G., Macpherson, E., Theodoridis, G. A., & Wilson, I. D. (2008). Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. J Chromatogr B Analyt Technol Biomed Life Sci, 871, 299–305.
Gika, H. G., Theodoridis, G. A., Wingate, J. E., & Wilson, I. D. (2007). Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. Journal of Proteome Research, 6, 3291–3303.
de Groot, P., Scheithauer, T., Bakker, G. J., Prodan, A., Levin, E., Khan, M. T., et al. (2019). Donor metabolic characteristics drive effects of faecalmicrobiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut, 69(3), 502–512.
Hollister, E. B., Oezguen, N., Chumpitazi, B. P., Luna, R. A., Weidler, E. M., Rubio-Gonzales, M., et al. (2019). Leveraging human microbiome features to diagnose and stratify children with irritable bowel syndrome. The Journal of Molecular Diagnostics, 21, 449–461.
Hu, J. R., Grams, M. E., Coresh, J., Hwang, S., Kovesdy, C. P., Guallar, E., et al. (2019). Serum metabolites and cardiac death in patients on hemodialysis. Clinical Journal of the American Society of Nephrology, 14, 747–749.
Ilhan, Z. E., Laniewski, P., Thomas, N., Roe, D. J., Chase, D. M., & Herbst-Kralovetz, M. M. (2019). Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine, 44, 675–690.
ISO 9000: (2015). Quality management systems-fundamentals and vocabulary, Switzerland, International Organization for Standardization.
Isganaitis, E., Venditti, S., Matthews, T. J., Lerin, C., Demerath, E. W., & Fields, D. A. (2019). Maternal obesity and the human milk metabolome: associations with infant body composition and postnatal weight gain. American Journal of Clinical Nutrition, 110(1), 111–120.
Kauffmann, H. M., Kamp, H., Fuchs, R., Chorley, B. N., Deferme, L., Ebbels, T., et al. (2017). Framework for the quality assurance of 'omics technologies considering GLP requirements. Regulatory Toxicology and Pharmacology, 91(Suppl 1), S27–S35.
Kelly, R. S., Boulin, A., Laranjo, N., Lee-Sarwar, K., Chu, S. H., Yadama, A. P., et al. (2019). Metabolomics and Communication Skills Development in Children (p. 9). Metabolites: Evidence from the Ages and Stages Questionnaire.
Kirwan, J. A., Brennan, L., Broadhurst, D., Fiehn, O., Cascante, M., Dunn, W. B., et al. (2018). Preanalytical processing and biobanking procedures of biological samples for metabolomics research: A white paper, community perspective (for "Precision Medicine and Pharmacometabolomics Task Group"-The Metabolomics Society Initiative). Clinical Chemistry, 64, 1158–1182.
Lains, I., Chung, W., Kelly, R. S., Gil, J., Marques, M., Barreto, P., et al. (2019). Human plasma metabolomics in age-related macular degeneration: Meta-analysis of two cohorts. Metabolites, 9(7), 127.
Manghani, K. (2011). Quality assurance: Importance of systems and standard operating procedures. Perspect Clin Res, 2, 34–37.
McCullough, M. L., Maliniak, M. L., Stevens, V. L., Carter, B. D., Hodge, R. A., & Wang, Y. (2019). Metabolomic markers of healthy dietary patterns in US postmenopausal women. American Journal of Clinical Nutrition, 109, 1439–1451.
Olson, C. A., Vuong, H. E., Yano, J. M., Liang, Q. Y., Nusbaum, D. J., & Hsiao, E. Y. (2018). The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell, 174, 497.
Playdon, M. C., Joshi, A. D., Tabung, F. K., Cheng, S., Henglin, M., Kim, A., et al. (2019). Metabolomics analytics workflow for epidemiological research: Perspectives from the consortium of metabolomics studies (COMETS). Metabolites, 9(7), 145.
Plaza-Diaz, J., Alvarez-Mercado, A. I., Ruiz-Marin, C. M., Reina-Perez, I., Perez-Alonso, A. J., Sanchez-Andujar, M. B., et al. (2019). Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study. BMC Cancer, 19, 495.
Ramirez, T., Daneshian, M., Kamp, H., Bois, F. Y., Clench, M. R., Coen, M., et al. (2013). Metabolomics in toxicology and preclinical research. Altex, 30, 209–225.
Rangel-Huerta, O. D., Gomez-Fernandez, A., de la Torre-Aguilar, M. J., Gil, A., Perez-Navero, J. L., Flores-Rojas, K., et al. (2019). Metabolic profiling in children with autism spectrum disorder with and without mental regression: preliminary results from a cross-sectional case-control study. Metabolomics, 15, 99.
Rebholz, C. M., Surapaneni, A., Levey, A. S., Sarnak, M. J., Inker, L. A., Appel, L. J., et al. (2019). The serum metabolome identifies biomarkers of dietary acid load in 2 studies of adults with chronic kidney disease. Journal of Nutrition, 149, 578–585.
Sangster, T., Major, H., Plumb, R., Wilson, A. J., & Wilson, I. D. (2006). A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst, 131, 1075–1078.
Sato, S., Basse, A. L., Schonke, M., Chen, S., Samad, M., Altintas, A., et al. (2019). Time of exercise specifies the impact on muscle metabolic pathways and systemic energy homeostasis. Cell Metabolism, 30(92–110), e4.
Shi, M., Bazzano, L. A., He, J., Gu, X., Li, C., Li, S., et al. (2019). Novel serum metabolites associate with cognition phenotypes among bogalusa heart study participants. Aging (Albany NY), 11, 5124–5139.
Shin, S. Y., Fauman, E. B., Petersen, A. K., Krumsiek, J., Santos, R., Huang, J., et al. (2014). An atlas of genetic influences on human blood metabolites. Nature Genetics, 46, 543–550.
Simon-Manso, Y., Lowenthal, M. S., Kilpatrick, L. E., Sampson, M. L., Telu, K. H., Rudnick, P. A., et al. (2013). Metabolite profiling of a NIST standard reference material for human plasma (SRM 1950): GC-MS, LC-MS, NMR, and clinical laboratory analyses, libraries, and web-based resources. Analytical Chemistry, 85, 11725–11731.
Smilde, A. K., van der Werf, M. J., Bijlsma, S., & van derWerffJellema, B. J. R. H. (2005). Fusion of mass spectrometry-based metabolomics data. Analytical Chemistry, 77, 6729–6736.
Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. A., et al. (2007). Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics, 3, 211–221.
Tang, W., Putluri, V., Ambati, C. R., Dorsey, T. H., Putluri, N., & Ambs, S. (2019). Liver- and microbiome-derived bile acids accumulate in human breast tumors and inhibit growth and improve patient survival. Clinical Cancer Research, 25, 5972–5983.
Tziotzios, C., Petridis, C., Dand, N., Ainali, C., Saklatvala, J. R., Pullabhatla, V., et al. (2019). Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02. Nat Commun, 10, 1150.
Viant, M. R., Ebbels, T. M. D., Beger, R. D., Ekman, D. R., Epps, D. J. T., Kamp, H., et al. (2019). Use cases, best practice and reporting standards for metabolomics in regulatory toxicology. Nat Commun, 10, 3041.
Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., et al. (2016). The FAIR guiding principles for scientific data management and stewardship. Sci Data, 3, 160018.
Wilmanski, T., Rappaport, N., Earls, J. C., Magis, A. T., Manor, O., Lovejoy, J., et al. (2019). Blood metabolome predicts gut microbiome alpha-diversity in humans. Nature Biotechnology, 37, 1217–1228.
Wittemans, L. B. L., Lotta, L. A., Oliver-Williams, C., Stewart, I. D., Surendran, P., Karthikeyan, S., et al. (2019). Assessing the causal association of glycine with risk of cardio-metabolic diseases. Nat Commun, 10, 1060.
Yu, B., Flexeder, C., McGarrah, R. W., Wyss, A., Morrison, A. C., North, K. E., et al. (2019). Metabolomics identifies novel blood biomarkers of pulmonary function and COPD in the general population. Metabolites, 9(4), 61.
Zambrana, L. E., McKeen, S., Ibrahim, H., Zarei, I., Borresen, E. C., Doumbia, L., et al. (2019). Rice bran supplementation modulates growth, microbiota and metabolome in weaning infants: A clinical trial in Nicaragua and Mali. Sci Rep, 9, 13919.
Zelena, E., Dunn, W. B., Broadhurst, D., Francis-McIntyre, S., Carroll, K. M., Begley, P., O'Hagan, S., Knowles, J. D., Halsall, A., Consortium, H., Wilson, I. D. & Kell, D. B. (2009). Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Analytical Chemistry, 81, 1357–1364.
Conflict of interest
The authors have no conflict of interest to declare.
Research involving human and animal participants
This article does not contain any studies with human and/or animal participants performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The opinions expressed in this publication are those of the authors and do not necessarily represent the views or policies of the US. Environmental Protection Agency, the US. Food and Drug Administration or the National Institute of Standards and Technology.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Evans, A.M., O’Donovan, C., Playdon, M. et al. Dissemination and analysis of the quality assurance (QA) and quality control (QC) practices of LC–MS based untargeted metabolomics practitioners. Metabolomics 16, 113 (2020). https://doi.org/10.1007/s11306-020-01728-5
- Quality assurance
- Quality control
- Untargeted metabolomics
- Metabolomics quality assurance and quality control consortium (mQACC)